Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-cash Items: 2022-2025

Historic Non-cash Items for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $31.1 million.

  • Taysha Gene Therapies' Non-cash Items rose 92.18% to $31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year increase of 92.18%. This contributed to the annual value of $15.5 million for FY2024, which is 690.82% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Non-cash Items stood at $31.1 million, which was up 40.24% from $22.2 million recorded in Q2 2025.
  • Taysha Gene Therapies' Non-cash Items' 5-year high stood at $47.4 million during Q1 2022, with a 5-year trough of $62,000 in Q4 2022.
  • Its 3-year average for Non-cash Items is $16.0 million, with a median of $16.2 million in 2024.
  • Data for Taysha Gene Therapies' Non-cash Items shows a peak YoY increase of 3,061.29% (in 2023) and a maximum YoY decrease of 73.42% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Non-cash Items (Quarterly) stood at $62,000 in 2022, then soared by 3,061.29% to $2.0 million in 2023, then spiked by 690.82% to $15.5 million in 2024, then skyrocketed by 92.18% to $31.1 million in 2025.
  • Its Non-cash Items stands at $31.1 million for Q3 2025, versus $22.2 million for Q2 2025 and $22.2 million for Q1 2025.